Ryan Maley - MIDAS

Blog Archives

New Manchester office as Riverview Law eyes major recruitment drive and awards additional training contracts

Following new contract wins and the expansion of work with existing customers, Riverview Law is relocating to larger premises in Manchester on 1 September to accommodate its growing team.

The move to Delta House in Wythenshawe comes 17 months after the business first opened in Manchester. This larger space, combined with the Wirral Service Delivery Centre, will enable Riverview to recruit up to 60 more team members, including solicitors, paralegals, client managers and data analysts, over the next year, and provide an option to take additional space in line with future business growth.

Previously, 20 staff worked from the Manchester office with each working between the city and the business’s headquarters in the Wirral.

The new state-of-the-art office provides Riverview Law with enhanced multi-site disaster recovery and IT resilience, meaning that it can provide client services in an ever more secure business environment.

Riverview Law has recently awarded two training contracts to existing members of the team to join its two-year solicitor training programme, which it first launched in September 2014. Susannah Brumby and Harriet Clayton will commence their training contracts this October. The first cohort of seven trainees finishes in September, with the second group of six trainees now almost a year into their training.

Riverview Law’s Operations Director, Katy Robson, says: “Our continued growth is due to increasing customer demand and Manchester provides an excellent talent pool to meet it. Increasingly, our corporate customers demand a higher standard of IT and data security and we must be able to meet and exceed this expectation to grow existing contracts and win new business. Our new office enables us to provide this important reassurance.

“We are also thrilled to have offered two more training contracts this year and to have our first trainee solicitors qualifying in September. Since we launched our trainee programme in 2014 we have awarded 15 trainee contracts and are committed to continuing the development and progression of all Riverview Law team members.”

Riverview Law has three UK locations – London, Manchester and Wirral – and two US locations – New Jersey and New York.

Further details about existing vacancies can be found on the Riverview Law website Join Us.

For further information, please contact:

Clare Rice, Black Letter Communications, Tel: +44 (0) 3567 1208 or email clare.rice@blacklettercommunications.co.uk

Notes to editors:

  1. Riverview Law’s new office is located at Delta House, Wavell Road, Wythenshawe, Manchester M22 5QZ.

About Riverview Law

Riverview Law provides ‘Legal input. Business output.’ to the in-house legal, risk, compliance and related functions of large corporations. It helps in-house teams evolve their legal operating model by providing prototyping consultancy, managed services and software and automation tools. Riverview Law is a technology-led business with deep legal domain expertise.

Riverview Law Limited is a company registered in England and Wales with registered number 7650291.

Riverview Law Limited is authorised and regulated by the Solicitors Regulation Authority (SRA) with SRA number 612745.

Universities unite to explore opportunities to train extra medics


The University of Manchester, the University of Salford and Manchester Metropolitan University are working together to explore proposals to train health professionals starting with a new independent, international medical school to train more doctors.

The proposals will see the extension of medical training in the North West.  This is in addition to the work already carried out by The University of Manchester’s own medical school, which has been educating doctors since 1874.

The proposal draws on the breadth of experience across all three universities in educating and training healthcare professionals. The new school will have an international focus, and will allow the most talented applicants from abroad to benefit from the breadth of skills and knowledge at all three universities.

The principles of the future collaboration, agreed on Friday, July 29, by the three university vice-chancellors*, represents a further development in the devolution of Greater Manchester’s healthcare system, so-called ‘DevoManc’. The emphasis is on the needs of Greater Manchester and the opportunity to have a ‘one Manchester’ focus has led to even greater cooperation between universities, the NHS and public bodies, to the benefit of the region’s population.

A joint statement by the three universities said: “Our discussions are at an early stage, but teaching more medical students right here in Greater Manchester is an exciting prospect. This is the first stage in the three universities developing a co-ordinated approach to healthcare education in the region to help address our local needs and priorities.

“By combining our knowledge, expertise, facilities and stakeholder networks we can offer world class opportunities which are highly attractive and accessible in a rapidly changing landscape for medical and health professionals in the UK and globally.”


*Professor Helen Marshall (University of Salford)

Professor Malcolm Press (Manchester Metropolitan University)

Dame Professor Nancy Rothwell (The University of Manchester)

Manchester strengthens ties with India to signify new era for bilateral trade

MII vector (2)

  • High Commission of India and Manchester host event to strengthen bilateral trade
  • Opportunity for Manchester to partner with India to help deliver economic development policy
  • India’s growing economy looks to Manchester for collaboration

Forging long-term relationships, harnessing bilateral trade and collaboration between Manchester and India is crucial to boosting the country’s thriving economy. This will be Deputy High Commissioner Dr Virander Paul’s resounding message at Make in India, Innovate with Manchester.

Make in India, Innovate with Manchester is a significant event taking place at the city’s Town Hall on 22 June, bringing together Indian businesses interested in trading with India and Indian businesses seeking collaborative opportunities in Greater Manchester. The event, hosted by MIDAS, Manchester’s inward investment agency (part of Manchester Growth Company) and the High Commission of India, is supported by the Confederation of Indian Industry, UKTI and Deloitte. It will enable delegates to better understand the bilateral trade, export and R&D collaboration opportunities presented by Prime Minister Modi’s initiative and how the city region is strengthening ties with India.

Since Prime Minister Modi launched Make in India, the country’s economic growth policy focused on fostering investment, innovation, protecting intellectual property and building world-class manufacturing, it has become clear it presents a real opportunity for Greater Manchester. Both Manchester and the High Commission of India have put increasing resources and energies into fully exploiting the opportunity and forging closer ties.

India is a critical market for the UK in terms of inward investment, outbound export, education and tourism. EY UK Attractiveness Survey 2016 revealed India was one of Manchester’s key markets for foreign direct investment and it is clear that Indian businesses are investing in the city. More specifically some of India’s key companies have invested in the region, these include Aegis, Vistaar Productions at MediaCityUK, Hero Cycles, State Bank of India and recently, HCL Technologies’ innovation partnership with Manchester United Football Club.

Highlighting the mutually beneficial India-UK economic engagement, Dr Virander Paul, said: “The Make in India initiative and other flagship programmes of the Government of India offer tremendous opportunities for foreign investors.

“Manchester is one of the active centres in the country, remaining in constant touch with the High Commission and Indian industry in diverse areas of trade and investments, life sciences and healthcare and higher education.”

Greater Manchester’s heritage in innovation and science, which has seen the region being recognised as European City of Science 2016, make it the ideal partner for Make in India. The universities expertise in areas such as advanced materials and manufacturing, 3D printing and life sciences provides unparalleled R&D opportunities for both industry and educational establishments.

Key speakers at Make in India, Innovate with Manchester include Dr Virander Paul, Tony Lloyd, Mayor of Greater Manchester, Tim Newns, Chief Executive of MIDAS, Manchester’s inward investment agency, Professor Luke Georghiou, Vice-President for Research and Innovation, University of Manchester,Shuchita Sonalika, UK Director, Confederation of Indian Industry and Bhupendra Nagar, Associate General Manager, HCL Technologies. Other companies attending the event will include Air India and Times of India.

Councillor Richard Farnell, Lead Member for Internationalisation and Marketing, Greater Manchester Combined Authority, said: “Positioning Greater Manchester on the global stage and attracting international investment is essential to growing our economy. This is evident with the increasing number of businesses taking premises across the city.

“The Greater Manchester Internationalisation Strategy names India as one of the city region’s six priority markets and we recognise India as a key partner. Our innovations within key sectors complement those developing in India, like R&D and Advanced Manufacturing, and the country’s economic policy is the perfect bridge to strengthening existing ties with our Indian partners.”

Tim Newns, chief executive of MIDAS, said: “Greater Manchester has traded with India since the Victorian era and Make in India, Innovate with Manchester provides us with the opportunity to collaborate and take this relationship to the next level. Greater Manchester has the skills and expertise in innovation, through our universities and private companies, to support India’s ambitions whilst also fuelling the ambitions of our local companies and research institutions which can add significant value.

“In Manchester 53,000 residents are of Indian heritage with multiple businesses in the city region being Indian-owned, adding to the fabric of our dynamic society. We are proud to welcome the Deputy High Commissioner to Manchester and hope this event symbolises the importance of bilateral trade and inward investment, developed through new and existing relationships.”

Greater Manchester Healthcare Achieves World First with Initial Results of Salford Lung Study

Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’  

Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice

The highly anticipated results from the Salford Lung Study were announced by GSK on 24th May 2016.

Healthcare professionals from eight organisations across Greater Manchester have collaborated to deliver the initial results of the Salford Lung Study (SLS). The study involved over 2,800 consenting patients, supported by 80 GP practices and 130 pharmacies in Salford and the surrounding Greater Manchester area.

This ground-breaking study, sponsored by GSK, examined the safety and effectiveness of a new treatment for chronic obstructive pulmonary disease (COPD). This was delivered in partnership with NorthWest EHealth (NWEH), The University of Manchester, Salford Royal NHS Foundation Trust, CK Aspire, Salford CCG, University Hospital South Manchester, South Manchester CCG and NIHR Clinical Research Network: Greater Manchester.

It is the world’s first digitally enhanced Randomised Controlled Trial (RCT) to include a broad and inclusive population of patients in an everyday clinical practice setting, embracing a novel approach to clinical trial design. This provides researchers with a breadth of clinical data that demonstrates the healthcare interactions of the everyday lives of patients and the way they use their medicines.

Conventional RCTs are usually conducted following strict inclusion criteria, which often exclude those patients with other multiple conditions. SLS was designed to include those patients who would often be excluded from a traditional randomised trial, for example individuals also being treated for other chronic diseases. This inclusive approach is important because it is more realistic of everyday practice and is therefore representative of a much wider patient population. The data provided by SLS will complement the existing data provided by the conventional RCT.

This collaborative study was placed in Salford because of the existing infrastructure of integrated electronic health medical records. The study relied on bespoke software, developed by NWEH and securely hosted within the NHS network that integrated the electronic medical records of consenting patients across all of their everyday interactions with their GPs, pharmacists and hospitals. This linked database system allowed close monitoring of patients’ safety in near real-time, but with minimal intrusion into their everyday lives.

By collecting healthcare information both quickly and efficiently, in line with best practice guidelines for security of patient data, the system offers responsiveness to patient safety, high quality data and short timelines for studies.

This digitally enhanced RCT design is a new and innovative approach to clinical trials; it is anticipated that the study methodology and underpinning technology could be used in future studies, not just in Greater Manchester but worldwide.

Sir David Dalton, Salford Royal Foundation Trust, Chief Executive, said: “Salford has a rich history of pioneering health care and is now building one of the most innovative environments in the UK for conducting patient-focused health research and translating it into patient benefit. We are delighted that this ground-breaking study has taken place in Salford as a result of our close collaboration with NorthWest EHealth, GSK and Salford CCG. Together we are at the forefront of the development of healthcare focused on the needs of patients by providing modern, innovative and cost-effective care, embracing technologies, and ensuring that patients have the opportunity to take part in research. The combination of our pioneering approach to integrated care and our integrated information systems have made this study possible.”

Professor Martin Gibson, NorthWest EHealth, Chief Executive, said: “This is not about Big Data, this is about understanding the way patients interact with medications in their everyday lives. Our unique technology supports understanding of NHS data to bring the right drugs to market quicker, whilst providing timely and accurate information on safety and cost for payers and patients alike.”

NorthWest EHealth’s Contribution to the Salford Lung Study

NWEH is a UK based Academic and NHS collaboration which specialises in leveraging existing Electronic Health Records (EHR) to develop medicines more quickly, with improved safety monitoring for the benefit of patients, pharmaceutical companies, and payers.

  • NWEH has led delivery on all the validated IT and EHR data aspects of the Salford Lung Study (SLS) robust Randomised Clinical Trial (RCT).
  • NWEH has demonstrated that it is able to help improve patient recruitment, reduce study costs, increase patient safety (through near real-time safety monitoring), and provide better clinical trial data that has greater breadth and depth (i.e. all Primary, Secondary and Pharmacy EHR Data for study subjects both during, and before, their time on the trial).
  • The technologies that NWEH have developed for use of existing EHR for robust RCTs, combined with their secure management of data within the N3*, are proven, established and replicable not only in the UK but in other digitised health economies across the globe.


Researchers, clinicians and industry gather to celebrate the launch of Manchester Molecular Pathology Centre

Around 100 delegates from across the University, NHS organisations and industry attended the inaugural showcase Manchester Molecular Pathology Innovation Centre event, held in Citylabs, on Thursday 28th April.

Delegates at the event included academic and clinical staff from across the Manchester Academic Health Science Centre and wider, industrial stakeholders, and representatives from policymakers and other molecular pathology nodes across the UK. All were keen to find out more about MMPathICs remit to deliver new biomarker based tests and in vitro diagnostics to the clinic and opportunities for engagement with the initiative.

Opening the event, Professor Ian Greer stressed the strategic importance of MMPathIC for Manchester’s ambitions to be world leading in delivering precision medicine solutions to patients. Professor Greer said “Manchester’s molecular pathology node will play a key role in translating the outstanding stratified medicine discovery research already ongoing locally, through to development and roll out of tests to into the NHS”. Professor Greer also noted that the co-funding of MMPathIC by both the Medical Research Council and the Engineering and Physical Sciences Council highlights the need and opportunity to work across traditional disciplinary boundaries.

Professor Tony Freemont, MMPathIC Director, outlined the exciting opportunities offered through MMPathIC. Professor Freemont said “MMPathIC has recruited a great team of experts who can help researchers and industry deliver biomarker based tests to the clinic or market”. Addressing the audience, Professor Freemont went on to highlight the early successes of MMPathIC since it’s official start date of 1st October 2015, which includes a number of funded projects in development with industry and academic partners.

The importance of joint working with external stakeholders such as the National Institute for Health and Care Excellence (NICE) was also flagged and Carla Deakin, Associate Director of the Diagnostics Assessment Programme outlined the role NICE plays in the development to adoption landscape.

Much of the MMPathIC funding support is to build an infrastructure of cutting edge expertise such as health informatics, health economics and text mining- and some of these newly recruited research fellows and other key staff gave presentations highlighting the opportunities offered by their particular disciplines.

The commercial potential of molecular pathology were further emphasised by keynote speaker, Dr Stephen Little, CEA of local diagnostic company, Premaitha, in an entertaining and informative overview of his own experiences of bringing molecular pathology tools to the market and the future business opportunities he saw.

Reflecting on the day, Professor Freemont said “The interest we’ve already had from organisations wanting to work with us has been great, but we want to continue to expand our community of companies, academics and clinicians with whom we work. We urge anyone who wishes to find out more about MMPathIC or the potential for collaboration to get in touch”.

About MMPathIC

MMPathIC is one of a network of six molecular pathology nodes across the UK. The University of Manchester was successful in securing nearly £3M funding for 4 years from 1st October 2015 from the Medical Research Council and the Engineering and Physical Sciences Council to set to establish MMPathIC- this was supplemented by an additional £1.5M of industry and institutional commitment.

Contact Us

Contact us online or call
+44 (0) 161 237 4470